anastrozole has been researched along with Breast Neoplasms, Male in 5 studies
Breast Neoplasms, Male: Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endocrine therapy in patients with breast cancer can be limited by the problem of resistance." | 6.76 | A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. ( Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H, 2011) |
| "Endocrine therapy in patients with breast cancer can be limited by the problem of resistance." | 2.76 | A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. ( Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H, 2011) |
| "Anastrozole has excellent antitumor activity in postmenopausal women, but no data exist on its efficacy in men." | 1.31 | Efficacy of anastrozole in male breast cancer. ( Buzdar, AU; Giordano, SH; Hortobagyi, GN; Valero, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doyen, J | 1 |
| Italiano, A | 1 |
| Largillier, R | 1 |
| Ferrero, JM | 1 |
| Fontana, X | 1 |
| Thyss, A | 1 |
| Massarweh, S | 1 |
| Tham, YL | 1 |
| Huang, J | 1 |
| Sexton, K | 1 |
| Weiss, H | 1 |
| Tsimelzon, A | 1 |
| Beyer, A | 1 |
| Rimawi, M | 1 |
| Cai, WY | 1 |
| Hilsenbeck, S | 1 |
| Fuqua, S | 1 |
| Elledge, R | 1 |
| Giordano, SH | 2 |
| Hortobagyi, GN | 2 |
| Carmona-Bayonas, A | 1 |
| Valero, V | 1 |
| Buzdar, AU | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer[NCT00206414] | Phase 2 | 15 participants (Actual) | Interventional | 2003-01-31 | Terminated (stopped due to Difficulty accruing subjects the study accrual was closed) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for anastrozole and Breast Neoplasms, Male
| Article | Year |
|---|---|
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2011 |
4 other studies available for anastrozole and Breast Neoplasms, Male
| Article | Year |
|---|---|
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aroma | 2010 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2006 |
Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer.
Topics: Adult; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2007 |
Efficacy of anastrozole in male breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Ne | 2002 |